Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Mounjaro), chronic weight management (under the brand name Zepbound), and most recently in 2024, for the treatment of adults with moderate-to-severe obstructive sleep apnea who have obesity or are overweight with at least one weight-related comorbidity
Its found naturally in your blood, saliva, and tissues
Not in Parkinsons, but two years ago another large study suggested that GLP-1R agonist use was associated with lower mortality than other diabetes treatments
If you take too much Tirzepatide, call your healthcare provider
Otherwise, I started using the gym in my building four times a week walking uphill
En los ensayos clnicos publicados, la tirzepatida (Zepbound) mostr una prdida de peso promedio mayor que la semaglutida